PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.68 - 0.75
0.33 - 0.86
12.91M / 4.66M (Avg.)
35.00 | 0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.84%
Negative revenue growth while 3606.HK stands at 25.58%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
17.03%
Gross profit growth at 50-75% of 3606.HK's 27.47%. Martin Whitman would question if cost structure or brand is lagging.
39.17%
EBIT growth above 1.5x 3606.HK's 15.05%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
39.17%
Operating income growth similar to 3606.HK's 40.77%. Walter Schloss would assume both share comparable operational structures.
12.12%
Net income growth under 50% of 3606.HK's 34.82%. Michael Burry would suspect the firm is falling well behind a key competitor.
13.73%
EPS growth under 50% of 3606.HK's 34.48%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
13.73%
Diluted EPS growth under 50% of 3606.HK's 34.48%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-1.45%
Share reduction while 3606.HK is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.36%
Reduced diluted shares while 3606.HK is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-140.53%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-128.18%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
48403.57%
10Y revenue/share CAGR above 1.5x 3606.HK's 252.47%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
21.62%
5Y revenue/share CAGR under 50% of 3606.HK's 60.11%. Michael Burry would suspect a significant competitive gap or product weakness.
2.09%
3Y revenue/share CAGR under 50% of 3606.HK's 31.05%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-54872.48%
Negative 10Y OCF/share CAGR while 3606.HK stands at 35.66%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-12824.71%
Negative 5Y OCF/share CAGR while 3606.HK is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-708.35%
Negative 3Y OCF/share CAGR while 3606.HK stands at 29.01%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
231.68%
Net income/share CAGR at 50-75% of 3606.HK's 392.11%. Martin Whitman might question if the firm’s product or cost base lags behind.
3699.57%
5Y net income/share CAGR above 1.5x 3606.HK's 131.14%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
574.70%
3Y net income/share CAGR above 1.5x 3606.HK's 32.94%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
96.16%
5Y equity/share CAGR at 50-75% of 3606.HK's 138.39%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
39.07%
Below 50% of 3606.HK's 83.33%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
No Data
No Data available this quarter, please select a different quarter.
-23.04%
Firm’s AR is declining while 3606.HK shows 23.74%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
15.68%
We show growth while 3606.HK is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-13.03%
Negative asset growth while 3606.HK invests at 5.23%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
7.65%
1.25-1.5x 3606.HK's 6.91%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
2122.61%
Debt growth far above 3606.HK's 2.29%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-25.80%
Our R&D shrinks while 3606.HK invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
25.32%
We expand SG&A while 3606.HK cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.